Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS

Takeshi Sugio, Kohta Miyawaki, Koji Kato, Kensuke Sasaki, Kyohei Yamada, Javeed Iqbal, Toshihiro Miyamoto, Koichi Ohshima, Takahiro Maeda, Hiroaki Miyoshi, Koichi Akashi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Peripheral T-cell lymphoma (PTCL), not otherwise specified (PTCL-NOS) is among the most common disease subtypes of PTCL, one that exhibits heterogeneous clinicopathological features. Although multiple disease-stratification models, including the cell-of-origin or gene-expression profiling methods, have been proposed for this condition, their clinical significance remains unclear. To establish a clinically meaningful stratification model, we analyzed gene-expression signatures of tumors and tumor-infiltrating immune cells using the nCounter system, which enables accurate quantification of low abundance and/or highly fragmented transcripts. To do so, we assessed transcripts of 120 genes related to cancer or immune cells using tumor samples from 68 newly diagnosed PTCL-NOS patients and validated findings by immunofluorescence in tumor sections. We show that gene-expression signatures representing tumor-infiltrating immune cells, but not those of cancerous T cells, dictate patient clinical outcomes. Cases exhibiting both B-cell and dendritic cell (DC) signatures (BD subgroup) showed favorable clinical outcomes, whereas those exhibiting neither B-cell nor DC signatures (non-BD subgroup) showed extremely poor prognosis. Notably, half of the non-BD cases exhibited a macrophage signature, and macrophage infiltration was evident in those cases, as revealed by immunofluorescence. Importantly, tumor-infiltrating macrophages expressed the immune-checkpoint molecules programmed death ligand 1/2 and indoleamine 2, 3-dioxygenase 1 at high levels, suggesting that checkpoint inhibitors could serve as therapeutic options for patients in this subgroup. Our study identifies clinically distinct subgroups of PTCL-NOS and suggests a novel therapeutic strategy for 1 subgroup associated with a poor prognosis. Our data also suggest functional interactions between cancerous T cells and tumor-infiltrating immune cells potentially relevant to PTCL-NOS pathogenesis.

Original languageEnglish (US)
Pages (from-to)2242-2252
Number of pages11
JournalBlood Advances
Volume2
Issue number17
DOIs
StatePublished - Sep 11 2018

Fingerprint

Peripheral T-Cell Lymphoma
Neoplasms
Macrophages
Transcriptome
Dendritic Cells
Fluorescent Antibody Technique
B-Lymphocytes
Indoleamine-Pyrrole 2,3,-Dioxygenase
T-Lymphocytes
Gene Expression Profiling
Ligands

ASJC Scopus subject areas

  • Hematology

Cite this

Sugio, T., Miyawaki, K., Kato, K., Sasaki, K., Yamada, K., Iqbal, J., ... Akashi, K. (2018). Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Advances, 2(17), 2242-2252. https://doi.org/10.1182/pbloodadvances.2018018754

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. / Sugio, Takeshi; Miyawaki, Kohta; Kato, Koji; Sasaki, Kensuke; Yamada, Kyohei; Iqbal, Javeed; Miyamoto, Toshihiro; Ohshima, Koichi; Maeda, Takahiro; Miyoshi, Hiroaki; Akashi, Koichi.

In: Blood Advances, Vol. 2, No. 17, 11.09.2018, p. 2242-2252.

Research output: Contribution to journalArticle

Sugio, T, Miyawaki, K, Kato, K, Sasaki, K, Yamada, K, Iqbal, J, Miyamoto, T, Ohshima, K, Maeda, T, Miyoshi, H & Akashi, K 2018, 'Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS', Blood Advances, vol. 2, no. 17, pp. 2242-2252. https://doi.org/10.1182/pbloodadvances.2018018754
Sugio, Takeshi ; Miyawaki, Kohta ; Kato, Koji ; Sasaki, Kensuke ; Yamada, Kyohei ; Iqbal, Javeed ; Miyamoto, Toshihiro ; Ohshima, Koichi ; Maeda, Takahiro ; Miyoshi, Hiroaki ; Akashi, Koichi. / Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. In: Blood Advances. 2018 ; Vol. 2, No. 17. pp. 2242-2252.
@article{fc7b736408474267b5dd99f0b5b61c41,
title = "Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS",
abstract = "Peripheral T-cell lymphoma (PTCL), not otherwise specified (PTCL-NOS) is among the most common disease subtypes of PTCL, one that exhibits heterogeneous clinicopathological features. Although multiple disease-stratification models, including the cell-of-origin or gene-expression profiling methods, have been proposed for this condition, their clinical significance remains unclear. To establish a clinically meaningful stratification model, we analyzed gene-expression signatures of tumors and tumor-infiltrating immune cells using the nCounter system, which enables accurate quantification of low abundance and/or highly fragmented transcripts. To do so, we assessed transcripts of 120 genes related to cancer or immune cells using tumor samples from 68 newly diagnosed PTCL-NOS patients and validated findings by immunofluorescence in tumor sections. We show that gene-expression signatures representing tumor-infiltrating immune cells, but not those of cancerous T cells, dictate patient clinical outcomes. Cases exhibiting both B-cell and dendritic cell (DC) signatures (BD subgroup) showed favorable clinical outcomes, whereas those exhibiting neither B-cell nor DC signatures (non-BD subgroup) showed extremely poor prognosis. Notably, half of the non-BD cases exhibited a macrophage signature, and macrophage infiltration was evident in those cases, as revealed by immunofluorescence. Importantly, tumor-infiltrating macrophages expressed the immune-checkpoint molecules programmed death ligand 1/2 and indoleamine 2, 3-dioxygenase 1 at high levels, suggesting that checkpoint inhibitors could serve as therapeutic options for patients in this subgroup. Our study identifies clinically distinct subgroups of PTCL-NOS and suggests a novel therapeutic strategy for 1 subgroup associated with a poor prognosis. Our data also suggest functional interactions between cancerous T cells and tumor-infiltrating immune cells potentially relevant to PTCL-NOS pathogenesis.",
author = "Takeshi Sugio and Kohta Miyawaki and Koji Kato and Kensuke Sasaki and Kyohei Yamada and Javeed Iqbal and Toshihiro Miyamoto and Koichi Ohshima and Takahiro Maeda and Hiroaki Miyoshi and Koichi Akashi",
year = "2018",
month = "9",
day = "11",
doi = "10.1182/pbloodadvances.2018018754",
language = "English (US)",
volume = "2",
pages = "2242--2252",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS

AU - Sugio, Takeshi

AU - Miyawaki, Kohta

AU - Kato, Koji

AU - Sasaki, Kensuke

AU - Yamada, Kyohei

AU - Iqbal, Javeed

AU - Miyamoto, Toshihiro

AU - Ohshima, Koichi

AU - Maeda, Takahiro

AU - Miyoshi, Hiroaki

AU - Akashi, Koichi

PY - 2018/9/11

Y1 - 2018/9/11

N2 - Peripheral T-cell lymphoma (PTCL), not otherwise specified (PTCL-NOS) is among the most common disease subtypes of PTCL, one that exhibits heterogeneous clinicopathological features. Although multiple disease-stratification models, including the cell-of-origin or gene-expression profiling methods, have been proposed for this condition, their clinical significance remains unclear. To establish a clinically meaningful stratification model, we analyzed gene-expression signatures of tumors and tumor-infiltrating immune cells using the nCounter system, which enables accurate quantification of low abundance and/or highly fragmented transcripts. To do so, we assessed transcripts of 120 genes related to cancer or immune cells using tumor samples from 68 newly diagnosed PTCL-NOS patients and validated findings by immunofluorescence in tumor sections. We show that gene-expression signatures representing tumor-infiltrating immune cells, but not those of cancerous T cells, dictate patient clinical outcomes. Cases exhibiting both B-cell and dendritic cell (DC) signatures (BD subgroup) showed favorable clinical outcomes, whereas those exhibiting neither B-cell nor DC signatures (non-BD subgroup) showed extremely poor prognosis. Notably, half of the non-BD cases exhibited a macrophage signature, and macrophage infiltration was evident in those cases, as revealed by immunofluorescence. Importantly, tumor-infiltrating macrophages expressed the immune-checkpoint molecules programmed death ligand 1/2 and indoleamine 2, 3-dioxygenase 1 at high levels, suggesting that checkpoint inhibitors could serve as therapeutic options for patients in this subgroup. Our study identifies clinically distinct subgroups of PTCL-NOS and suggests a novel therapeutic strategy for 1 subgroup associated with a poor prognosis. Our data also suggest functional interactions between cancerous T cells and tumor-infiltrating immune cells potentially relevant to PTCL-NOS pathogenesis.

AB - Peripheral T-cell lymphoma (PTCL), not otherwise specified (PTCL-NOS) is among the most common disease subtypes of PTCL, one that exhibits heterogeneous clinicopathological features. Although multiple disease-stratification models, including the cell-of-origin or gene-expression profiling methods, have been proposed for this condition, their clinical significance remains unclear. To establish a clinically meaningful stratification model, we analyzed gene-expression signatures of tumors and tumor-infiltrating immune cells using the nCounter system, which enables accurate quantification of low abundance and/or highly fragmented transcripts. To do so, we assessed transcripts of 120 genes related to cancer or immune cells using tumor samples from 68 newly diagnosed PTCL-NOS patients and validated findings by immunofluorescence in tumor sections. We show that gene-expression signatures representing tumor-infiltrating immune cells, but not those of cancerous T cells, dictate patient clinical outcomes. Cases exhibiting both B-cell and dendritic cell (DC) signatures (BD subgroup) showed favorable clinical outcomes, whereas those exhibiting neither B-cell nor DC signatures (non-BD subgroup) showed extremely poor prognosis. Notably, half of the non-BD cases exhibited a macrophage signature, and macrophage infiltration was evident in those cases, as revealed by immunofluorescence. Importantly, tumor-infiltrating macrophages expressed the immune-checkpoint molecules programmed death ligand 1/2 and indoleamine 2, 3-dioxygenase 1 at high levels, suggesting that checkpoint inhibitors could serve as therapeutic options for patients in this subgroup. Our study identifies clinically distinct subgroups of PTCL-NOS and suggests a novel therapeutic strategy for 1 subgroup associated with a poor prognosis. Our data also suggest functional interactions between cancerous T cells and tumor-infiltrating immune cells potentially relevant to PTCL-NOS pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85065244965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065244965&partnerID=8YFLogxK

U2 - 10.1182/pbloodadvances.2018018754

DO - 10.1182/pbloodadvances.2018018754

M3 - Article

C2 - 30194138

AN - SCOPUS:85065244965

VL - 2

SP - 2242

EP - 2252

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 17

ER -